Deutsche Bank Maintains Buy on ESRX, WAG

Deutsche Bank has published a research report on Healthcare Technology & Distribution today, commenting on enrollment favors for the month of February concerning Express Scripts

and Walgreens

. In the report, Deutsche Bank writes, "Given the lack of resolution on the ESRX‐WAG dispute, there had been some expectations that ESRX's Medicare enrollment would decline (based on the thesis that the elderly population was more likely to opt for plans that had WAG within their network). The sequential increase in ESRX' enrollment counteracts this thesis and supports our view that ESRX will retain >95% of the 90 million scripts that WAG used to service. Given the anticipated benefit from the upcoming generic wave, as well as prospective upside from potential closure of its acquisition of MHS, we reiterate our Buy rating on both ESRX and MHS." Express Scripts is currently trading up $0.87 from yesterday's $51.16 closing price while Walgreens is trading down $0.24 from yesterday's $33.36 closing price.